In the MEDIOLA basket studies, all cohorts were histotype-limited, with the advanced breast and relapsed ovarian cancer cohorts permitting only germline BRCA1/2 alterations and platinum-sensitive disease [53, 54]. The gene discussed is BRCA1; the disease is ovarian carcinoma.